Lymphocyte News and Research

RSS

Study reveals immune rheostat maintaining skin barrier homeostasis

As the steadfast protector of the body's interior, the skin must be able to swiftly respond to stressors from the outside world and then return to a steady state in order to maintain everyday operations. Coordinating that agile response are epidermal stem cells, which produce the overlying protective layers of specialized skin cells sent to the surface while also maintaining a ready pool of new stem cells to draw from.

30 Oct 2026

Nearly one third of patients with advanced melanoma saw tumors disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy

Results from a clinical trial have revealed nearly one third (29.2 percent) of patients with advanced melanoma saw their tumors disappear completely on scans after receiving lifileucel TIL therapy alongside an immune checkpoint inhibitor, pembrolizumab, as a first-line treatment.

24 Oct 2026

Polymeric nanomedicine strategies improve solid tumor immunotherapy outcomes

Solid tumors are not merely collections of malignant cells but complex ecosystems comprising tumor cells, stromal cells, and the extracellular matrix (ECM).

9 Oct 2026

Terumo Blood and Cell Technologies partners with TrAMPoline Pharma to automate TIL therapy manufacturing for solid tumors

Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company advancing blood- and cell-based therapies worldwide, has entered a research collaboration with TrAMPoline Pharma and Eduardo Davila, PhD, at the University of Colorado to develop an automated manufacturing approach for tumor-infiltrating lymphocyte (TIL) therapies targeting solid tumors.

6 Oct 2026

Cannabis-derived nanovesicles showed early antitumor potential in mice

Researchers developed a Cannabis sativa hairy root culture system that produced stable plant-derived nanovesicles capable of promoting dendritic cell maturation and activating T-cell responses through TLR2- and TLR4-associated signaling. Oral administration also restored selected immune responses in immunosuppressed mice and suppressed tumor growth in an E.G7 lymphoma model, providing preliminary evidence for their immunomodulatory and antitumor potential.

15 Sep 2026

Ris-Rez improves survival in patients with relapsed small-cell lung cancer

Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy.

14 Sep 2026

MD Anderson trial challenges local consolidative therapy paradigm in NSCLC

Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Targeted nanoparticles strengthen anti-cancer immune responses in tumors

Adelaide University researchers have developed a new way of using mRNA technology to reprogram tumor-supporting immune cells and strengthen the body's anti-cancer immune response.

11 Sep 2026

Study links thymus radiation to worse lung cancer outcomes

Until recently, the thymus was thought to be of little use beyond puberty, but new research has shown that radiation to the organ is associated with worse outcomes in patients being treated for non-small cell lung cancer (NSCLC).

25 Aug 2026

A striking immune cell pattern emerges around a person’s 100th birthday

Single-cell immune profiling found that CD4 cytotoxic T lymphocytes become more abundant around age 100, showing stepwise differentiation and substantial clonal expansion. Ex vivo experiments also revealed cytokine plasticity within individual clones, supporting the hypothesis that these cells adapt to persistent antigens during healthy aging, although their direct role in longevity remains unproven.

23 Aug 2026

Dual immunotherapy with neoadjuvant chemotherapy shows encouraging activity in ERBB2-negative breast cancer

A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to phase 2 clinical trial results from the ongoing I-SPY2 clinical trial platform.

30 Jul 2026

Too little or too much iodine may push immunity off balance

This narrative review finds that adequate iodine supports thyroid hormone signaling, leukocyte metabolism, antioxidant defenses, and antimicrobial activity in humans and domesticated mammals. Both deficiency and sustained excess may impair immunity or promote thyroid inflammation, but precise immune-specific intake thresholds remain uncertain.

27 Jul 2026

MEK inhibition could limit T cell exhaustion and give a boost to immunotherapy

A major pillar of cancer immunotherapy involves stimulating T cells, the specialized killers of the immune system, to attack tumors.

23 Jul 2026

Dysregulation of immune regulator NF-κB drives major human diseases

NF‑κB controls genes involved in inflammation, immunity, cell survival, and proliferation. Triggered by cytokines (TNF‑α, IL‑1β), microbial products, or cellular stress, it translocates to the nucleus and induces pro‑inflammatory mediators.

13 Jul 2026

Gut-friendly diet linked to lower mortality risk in coronary heart disease

Using NHANES 2005-2018 data, researchers found that adults with coronary heart disease who had higher Dietary Index for Gut Microbiota scores had lower all-cause mortality risk. The association was nonlinear, strongest when scores reached 5 or higher, and remained observational rather than causal.

9 Jul 2026